Verona Pharma Plc : Pdmr Dealing & Issue Of Shares
August 10 2018 - 7:12AM
UK Regulatory
TIDMVRP
LONDON, Aug. 10, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that, on August 9, 2018, Dr. David
Ebsworth, Chairman of the Company, purchased 12,000 ordinary shares of 5
pence each in the Company (the "Ordinary Shares") at a price of 120.00
pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will
have an interest in the Company of 147,787 Ordinary Shares, representing
0.14% of the Company's issued share capital.
The notification set out below is provided in accordance with the
requirements of the EU Market Abuse Regulation.
The Company also announces that, on August 9, 2018, it issued 58,112 new
Ordinary Shares (the "New Ordinary Shares") following the vesting of
restricted stock units held by a former employee, Dr. Ken Newman.
Application will be made to the London Stock Exchange for the New
Ordinary Shares to be admitted to trading on AIM, with dealings expected
to commence on 16 August 2018 ("Admission"). Following Admission, the
Company will have a total of 105,075,513 Ordinary Shares in issue each
carrying one voting right. The Company does not hold any Ordinary Shares
in Treasury. This figure of 105,075,513 Ordinary Shares may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change
to their interest in, the share capital of the Company under the FCA's
Disclosure and Transparency Rules.
1 Details of the person discharging managerial responsibilities/person
closely associated
----------------------------------------------------------------------------
a) Name David Ebsworth
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Chairman
b) Initial Initial notification
notification/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Verona Pharma plc
----------------------- ---------------------------------------------------
b) LEI 213800EVI6O6J3TIAL06
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------------------
a) Description of the Ordinary Shares of 5 pence each
financial instrument,
type of instrument
Identification code GB00BYW2KH80
b) Nature of the David Ebsworth purchased 12,000 Ordinary Shares
transaction
c) Price(s) and volume(s) Price(s) Volume(s)
----------------------- ----------------------
120.00 pence per 12,000 Ordinary Shares
Ordinary Share
----------------------- ----------------------
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 9 August 2018
----------------------- -------------------------------------------------
f) Place of the London Stock Exchange, AIM
transaction
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
(END) Dow Jones Newswires
August 10, 2018 07:12 ET (11:12 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jul 2023 to Jul 2024